212 related articles for article (PubMed ID: 12612508)
1. Cost-effectiveness of screening a population with chronic gastroesophageal reflux.
Nietert PJ; Silverstein MD; Mokhashi MS; Kim CY; Glenn TF; Marsi VA; Hawes RH; Wallace MB
Gastrointest Endosc; 2003 Mar; 57(3):311-8. PubMed ID: 12612508
[TBL] [Abstract][Full Text] [Related]
2. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
[TBL] [Abstract][Full Text] [Related]
3. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
Gerson L; Lin OS
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
[TBL] [Abstract][Full Text] [Related]
4. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
[TBL] [Abstract][Full Text] [Related]
5. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
Provenzale D; Schmitt C; Wong JB
Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
[TBL] [Abstract][Full Text] [Related]
6. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
[TBL] [Abstract][Full Text] [Related]
7. Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett's esophagus in patients with GERD symptoms.
Honing J; Kievit W; Bookelaar J; Peters Y; Iyer PG; Siersema PD
Gastrointest Endosc; 2019 Apr; 89(4):712-722.e3. PubMed ID: 30385112
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
Gerson LB; Groeneveld PW; Triadafilopoulos G
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
[TBL] [Abstract][Full Text] [Related]
9. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
Heberle CR; Omidvari AH; Ali A; Kroep S; Kong CY; Inadomi JM; Rubenstein JH; Tramontano AC; Dowling EC; Hazelton WD; Luebeck EG; Lansdorp-Vogelaar I; Hur C
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1397-1404.e7. PubMed ID: 28238953
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.
Streitz JM; Ellis FH; Tilden RL; Erickson RV
Am J Gastroenterol; 1998 Jun; 93(6):911-5. PubMed ID: 9647017
[TBL] [Abstract][Full Text] [Related]
12. Cost-Analyses Studies in Barrett's Esophagus: What Is Their Utility?
Gerson LB
Gastroenterol Clin North Am; 2015 Jun; 44(2):425-38. PubMed ID: 26021203
[TBL] [Abstract][Full Text] [Related]
13. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
[TBL] [Abstract][Full Text] [Related]
14. A guide for surveillance of patients with Barrett's esophagus.
Provenzale D; Kemp JA; Arora S; Wong JB
Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
[TBL] [Abstract][Full Text] [Related]
15. Wide Area Transepithelial Sampling with Computer-Assisted Analysis (WATS
Singer ME; Smith MS
Dig Dis Sci; 2021 May; 66(5):1572-1579. PubMed ID: 32578042
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review.
Barbiere JM; Lyratzopoulos G
Gastroenterology; 2009 Dec; 137(6):1869-76. PubMed ID: 19840798
[TBL] [Abstract][Full Text] [Related]
17. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
[TBL] [Abstract][Full Text] [Related]
18. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
[TBL] [Abstract][Full Text] [Related]
19. Economic value of narrow-band imaging versus white light endoscopy for the diagnosis and surveillance of Barrett's esophagus: Cost-consequence model.
Furneri G; Klausnitzer R; Haycock L; Ihara Z
PLoS One; 2019; 14(3):e0212916. PubMed ID: 30865673
[TBL] [Abstract][Full Text] [Related]
20. Are screening and surveillance for Barrett's oesophagus really worthwhile?
Sharma P; Sidorenko EI
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i27-32. PubMed ID: 15711005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
